Eric Helmer

884 citations

18 papers · 497 indexed · h-index 8

Impact in

Immunology top 10%
- Psoriasis: Treatment and Pathogenesis
- Reproductive System and Pregnancy
Dermatology top 5%
- Dermatology and Skin Diseases

Papers in ⓘ

Pharmacology 3
- Pharmacogenetics and Drug Metabolism 3
Immunology 6
- Reproductive System and Pregnancy 3
- Immunodeficiency and Autoimmune Disorders 2

Co-authors: Xavier Mariette (5 shared papers)Marie Teil (5 shared papers)Frauke Förger (5 shared papers)Astrid van Tubergen (5 shared papers)Laura Shaughnessy (5 shared papers)Anna Moltó (5 shared papers)René-Marc Flipo (1 shared paper)Ann D. Flynn (4 shared papers)
Journals: Annals of the Rheumatic Diseases (3 papers)The Journal of Clinical Pharmacology (2 papers)European Journal of Pharmaceutical Sciences (1 paper)Clinical Pharmacology & Therapeutics (1 paper)British Journal of Clinical Pharmacology (1 paper)
Partner nations: Belgium United Kingdom United States

In The Last Decade

Eric Helmer

18 papers receiving 483 citations

Peers

Countries citing papers authored by Eric Helmer

Since Specialization

Citations

This map shows the geographic impact of Eric Helmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Helmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Helmer more than expected).

Fields of papers citing papers by Eric Helmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Helmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Helmer. The network helps show where Eric Helmer may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Helmer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Helmer Line = papers co-authored together Eric Helmer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study Annals of the Rheumatic Diseases ·Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D. Flynn, Anna Moltó, René-Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Haitian Wang, Eliza F. Chakravarty	2017	255
2	First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis British Journal of Clinical Pharmacology ·Sophie Glatt, Eric Helmer, Birgit Haier, Foteini Strimenopoulou, Graham Price, Pavan Vajjah, Olivier Harari, John M. Lambert, Stevan Shaw	2016	114
3	Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials The Journal of Clinical Pharmacology ·Ellen van der Aar, Julie Desrivot, Sonia Dupont, Bertrand Heckmann, Ann Fieuw, Simone Stutvoet, Liesbeth Fagard, Karen Van de Wal, Eric Helmer	2019	34
4	GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial European Respiratory Journal ·Irina Strâmbu, Christian A. Seemayer, Liesbeth Fagard, Paul A. Ford, Tom A.K. Van der Aa, Angela A. de Haas-Amatsaleh, Vikas Modgill, Eva Santermans, Eric Sondag, Eric Helmer, Toby M. Maher, Ulrich Costabel, Vincent Cottin	2022	27
5	First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases European Journal of Clinical Pharmacology ·Eric Helmer, Mark Watling, Emma Jones, D. Tytgat, Mark Jones, Rodger A. Allen, Andrew Payne, Annelize Koch, Eugene Healy	2017	13
6	Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration Clinical Pharmacology in Drug Development ·Eric Helmer, Ashley Willson, Christopher Brearley, Mark Westerhof, Stephane Delage, Iain Shaw, Ray Cooke, Sharan Sidhu	2021	9
7	OP0017 Lack of placental transfer of certolizumab pegol during pregnancy: results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study Annals of the Rheumatic Diseases ·Xavier Mariette, ADRIAN FLYNN, Frauke Förger, Anna Moltó, RM Flipo, Astrid van Tubergen, Laura Shaughnessy, J. A. Simpson, Marie Teil, Eric Helmer, M Wang, Eliza Chakravarty	2017	8
8	Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies Clinical Pharmacology in Drug Development ·Julie Desrivot, Tim Van Kaem, Lisa Allamassey, Eric Helmer	2021	7
9	Ziritaxestat Drug–Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition Clinical Pharmacology & Therapeutics ·Eric Helmer, Negin Karimian, Karen Van Assche, Ineke Seghers, Sandrine Le Tallec, Ganesh Cherala, Graham Scott, Florence Namour	2022	5
10	A Dual‐Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [¹⁴C]Seletalisib (UCB5857) in Healthy Subjects The Journal of Clinical Pharmacology ·Eric Helmer, Jean‐Marie Nicolas, Jeff Long, Ad F. Roffel, Emma Jones, Hugues Chanteux, Nieves Díaz, Holly Garratt, Tjerk Bosje	2017	5
11	GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects Clinical Pharmacology in Drug Development ·Helen Timmis, Tim Van Kaem, Julie Desrivot, Sonia Dupont, Luc Meuleners, Johan Beetens, Eric Helmer, Eva Santermans, Silke Huettner	2021	5
12	Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions European Journal of Pharmaceutical Sciences ·Jean‐Marie Nicolas, Hugues Chanteux, Johan Nicolaï, Frédéric Brouta, Delphine Viot, Marie‐Luce Rosseels, Eric Gillent, Pierre Bonnaillie, François‐Xavier Mathy, Jeff Long, Eric Helmer	2019	3
13	AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS) Annals of the Rheumatic Diseases ·Maria Juárez, Nieves Díaz, Geoffrey I. Johnston, Saba Nayar, Andrew Payne, Eric Helmer, Dionne Cain, Paulette Williams, Wan‐Fai Ng, Benjamin A. Fisher, Jacques‐Eric Gottenberg, Giuliana Guggino, Xavier Mariette, Marika Kvarnström, Valérie Devauchelle‐Pensec, J. Rosas, Juan Sánchez‐Bursón, Roberto Giacomelli, Francesca Barone, Simon Bowman	2019	3
14	Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from Crib, a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study Gastroenterology ·Bincy Abraham, Xavier Mariette, Ann D. Flynn, Frauke Förger, Anna Moltó, René‐Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza F. Chakravarty	2017	3
15	Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model Clinical and Translational Science ·Jérémy Perrier, Virginie Gualano, Eric Helmer, Florence Namour, Viera Lukáčová, Amit Taneja	2023	2
16	Lack of placental transfer of certolizumab pegol during pregnancy: Results from crib, a prospective, postmarketing, multicenter, pharmacokinetic study Reproductive Toxicology ·Xavier Mariette, Bincy Abraham, Ann D. Flynn, Frauke Förger, Anna Moltó, René‐Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza F. Chakravarty	2017	2
17	Abstract CT114: Data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into phase 1 in RCC/NSCLC Cancer Research ·Nieves Díaz, Holly Garratt, Aleksandra Zemla-Brown, M. J. Dominguez, Eric Helmer, Isabella Alt, Robert Sehlke, Norbert Hieger, Thomas Winkler-Penz, Christophe Boudesco, Gregory I. Vladimer, Tom Wilde, Philip Evans, Antoîne Italiano, Michael Krams	2023	1
18	Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study European Journal of Obstetrics & Gynecology and Reproductive Biology ·Xavier Mariette, Frauke Förger, Bincy Abraham, Ann D. Flynn, Anna Moltó, René‐Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Haitian Wang, Eliza F. Chakravarty	2019	1

About Eric Helmer

Eric Helmer is a scholar working on Pharmacology, Immunology, Genetics, Hematology and Physiology, having authored 18 papers that have together received 497 indexed citations. Recurring topics across this work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Pharmacogenetics and Drug Metabolism (3 papers), Reproductive System and Pregnancy (3 papers), Pregnancy and Medication Impact (3 papers), Pharmacological Effects and Toxicity Studies (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Immunodeficiency and Autoimmune Disorders (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). The work is most often cited by research in Immunology (301 citations), Dermatology (97 citations), Rheumatology (117 citations), Hematology (68 citations) and Public Health, Environmental and Occupational Health (144 citations). Eric Helmer has collaborated with scholars based in Belgium, United Kingdom and United States. Frequent co-authors include Xavier Mariette, Marie Teil, Frauke Förger, Astrid van Tubergen, Laura Shaughnessy, Anna Moltó, René-Marc Flipo, Ann D. Flynn, Maggie Haitian Wang and Eliza F. Chakravarty. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Clinical Pharmacology, European Journal of Pharmaceutical Sciences, Clinical Pharmacology & Therapeutics and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact